206 related articles for article (PubMed ID: 37864894)
1. Combination of MCL-1 and BCL-2 inhibitors is a promising approach for a host-directed therapy for tuberculosis.
Arnett E; Pahari S; Leopold Wager CM; Hernandez E; Bonifacio JR; Lumbreras M; Renshaw C; Montoya MJ; Opferman JT; Schlesinger LS
Biomed Pharmacother; 2023 Dec; 168():115738. PubMed ID: 37864894
[TBL] [Abstract][Full Text] [Related]
2. PPARγ is critical for Mycobacterium tuberculosis induction of Mcl-1 and limitation of human macrophage apoptosis.
Arnett E; Weaver AM; Woodyard KC; Montoya MJ; Li M; Hoang KV; Hayhurst A; Azad AK; Schlesinger LS
PLoS Pathog; 2018 Jun; 14(6):e1007100. PubMed ID: 29928066
[TBL] [Abstract][Full Text] [Related]
3. A small hairpin RNA targeting myeloid cell leukemia-1 enhances apoptosis in host macrophages infected with Mycobacterium tuberculosis.
Wang FY; Zhang YQ; Wang XM; Wang C; Wang XF; Wu JD; Wu F; Zhang WJ; Zhang L
J Microbiol; 2016 Apr; 54(4):330-7. PubMed ID: 27033209
[TBL] [Abstract][Full Text] [Related]
4. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
5. Repurposing Tamoxifen as Potential Host-Directed Therapeutic for Tuberculosis.
Boland R; Heemskerk MT; Forn-Cuní G; Korbee CJ; Walburg KV; Esselink JJ; Carvalho Dos Santos C; de Waal AM; van der Hoeven DCM; van der Sar E; de Ries AS; Xie J; Spaink HP; van der Vaart M; Haks MC; Meijer AH; Ottenhoff THM
mBio; 2023 Feb; 14(1):e0302422. PubMed ID: 36475748
[TBL] [Abstract][Full Text] [Related]
6. Adjunctive Host-Directed Therapy With Statins Improves Tuberculosis-Related Outcomes in Mice.
Dutta NK; Bruiners N; Zimmerman MD; Tan S; Dartois V; Gennaro ML; Karakousis PC
J Infect Dis; 2020 Mar; 221(7):1079-1087. PubMed ID: 31605489
[TBL] [Abstract][Full Text] [Related]
7. Survival of Mycobacterium tuberculosis in host macrophages involves resistance to apoptosis dependent upon induction of antiapoptotic Bcl-2 family member Mcl-1.
Sly LM; Hingley-Wilson SM; Reiner NE; McMaster WR
J Immunol; 2003 Jan; 170(1):430-7. PubMed ID: 12496428
[TBL] [Abstract][Full Text] [Related]
8. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
Kiran D; Podell BK; Chambers M; Basaraba RJ
Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
[TBL] [Abstract][Full Text] [Related]
9. Suppression of Mcl-1 induces apoptosis in mouse peritoneal macrophages infected with Mycobacterium tuberculosis.
Wang FY; Wang XM; Wang C; Wang XF; Zhang YQ; Wu JD; Wu F; Zhang WJ; Zhang L
Microbiol Immunol; 2016 Apr; 60(4):215-27. PubMed ID: 26876933
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker.
Richard DJ; Lena R; Bannister T; Blake N; Pierceall WE; Carlson NE; Keller CE; Koenig M; He Y; Minond D; Mishra J; Cameron M; Spicer T; Hodder P; Cardone MH
Bioorg Med Chem; 2013 Nov; 21(21):6642-9. PubMed ID: 23993674
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.
Niu Q; Deng H; Zhang Z; Xu Q; Luan S; Huang M; Liu D; Zhao L
Bioorg Med Chem Lett; 2021 Sep; 47():128215. PubMed ID: 34153472
[TBL] [Abstract][Full Text] [Related]
12. Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy.
Yamaguchi R; Lartigue L; Perkins G
Pharmacol Ther; 2019 Mar; 195():13-20. PubMed ID: 30347215
[TBL] [Abstract][Full Text] [Related]
13. Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy.
Mittal P; Singh S; Sinha R; Shrivastava A; Singh A; Singh IK
Int J Biol Macromol; 2021 Sep; 187():999-1018. PubMed ID: 34339789
[TBL] [Abstract][Full Text] [Related]
14. Small Molecule Mediated Restoration of Mitochondrial Function Augments Anti-Mycobacterial Activity of Human Macrophages Subjected to Cholesterol Induced Asymptomatic Dyslipidemia.
Asalla S; Mohareer K; Banerjee S
Front Cell Infect Microbiol; 2017; 7():439. PubMed ID: 29067283
[No Abstract] [Full Text] [Related]
15. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
[TBL] [Abstract][Full Text] [Related]
16. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
[TBL] [Abstract][Full Text] [Related]
17. Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy.
Zhu PJ; Yu ZZ; You QD; Jiang ZY
Drug Discov Today; 2020 Oct; 25(10):1873-1882. PubMed ID: 32771436
[TBL] [Abstract][Full Text] [Related]
18. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival.
Eichhorn JM; Alford SE; Sakurikar N; Chambers TC
Exp Cell Res; 2014 Apr; 322(2):415-24. PubMed ID: 24556425
[TBL] [Abstract][Full Text] [Related]
19. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
[TBL] [Abstract][Full Text] [Related]
20. Intracellular Accumulation of Novel and Clinically Used TB Drugs Potentiates Intracellular Synergy.
Tanner L; Mashabela GT; Omollo CC; de Wet TJ; Parkinson CJ; Warner DF; Haynes RK; Wiesner L
Microbiol Spectr; 2021 Oct; 9(2):e0043421. PubMed ID: 34585951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
